MYDA Advisors’s Cardiff Oncology CRDF Stock Holding History

MYDA Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,000	Closed	-$66K	–	165
2022 Q2	$66K	Buy	+30,000	New	+$50.2K	0.02%	171

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MYDA Advisors's CRDF Position: Q3 2022 in Review

MYDA Advisors sold out of Cardiff Oncology (CRDF) in Q3 2022, closing a stake of 30,000 shares — an estimated $66K sold.

MYDA Advisors first reported a position in CRDF in Q2 2022 and held it in 1 quarter. The position peaked at $66K in Q2 2022. 58 funds tracked by Wall St. Rank hold CRDF as of Q3 2022.

MYDA Advisors reported no remaining Cardiff Oncology position as of Q3 2022 after selling out during the quarter.
MYDA Advisors sold 30,000 Cardiff Oncology shares in Q3 2022, an estimated $66K.
MYDA Advisors first reported a position in Cardiff Oncology in Q2 2022 and held it in 1 quarter.
MYDA Advisors's Cardiff Oncology position peaked at $66K in Q2 2022.
58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2022.

Based on MYDA Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.